Do analysts recommend GLSI or CALT?

Greenwich LifeSciences currently has a consensus price target of $47.50, indicating a potential upside of 155.79%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Greenwich LifeSciences is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenwich LifeSciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, GLSI or ORIC?

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Greenwich LifeSciences N/A N/A -$19.36M -$1.57 N/A Oric Pharmaceuticals N/A N/A -$129.47M -$1.44 N/A

Is GLSI or ORIC more profitable?

Oric Pharmaceuticals' return on equity of -35.33% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Greenwich LifeSciences N/A -941.15% -368.53% Oric Pharmaceuticals N/A -35.33% -33.31%

Does the media refer more to GLSI or ORIC?

In the previous week, Greenwich LifeSciences had 3 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 6 mentions for Greenwich LifeSciences and 3 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 1.77 beat Greenwich LifeSciences' score of 1.02 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Greenwich LifeSciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oric Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings & valuation, CGEM or GLSI?

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A Greenwich LifeSciences N/A N/A -$19.36M -$1.57 N/A

Is CGEM or GLSI more profitable?

Cullinan Therapeutics' return on equity of -51.45% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -51.45% -47.64% Greenwich LifeSciences N/A -941.15% -368.53%

Does the media prefer CGEM or GLSI?

In the previous week, Greenwich LifeSciences had 2 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 6 mentions for Greenwich LifeSciences and 4 mentions for Cullinan Therapeutics. Greenwich LifeSciences' average media sentiment score of 1.02 beat Cullinan Therapeutics' score of 0.87 indicating that Greenwich LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Greenwich LifeSciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor XNCR or GLSI?

In the previous week, Xencor had 1 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 7 mentions for Xencor and 6 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 1.02 beat Xencor's score of 0.65 indicating that Greenwich LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Greenwich LifeSciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, SANA or GLSI?

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A Greenwich LifeSciences N/A N/A -$19.36M -$1.57 N/A

Is SANA or GLSI more profitable?

Sana Biotechnology's return on equity of -108.01% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Sana Biotechnology N/A -108.01% -40.68% Greenwich LifeSciences N/A -941.15% -368.53%

Does the media favor SANA or GLSI?

In the previous week, Greenwich LifeSciences had 2 more articles in the media than Sana Biotechnology. MarketBeat recorded 6 mentions for Greenwich LifeSciences and 4 mentions for Sana Biotechnology. Greenwich LifeSciences' average media sentiment score of 1.02 beat Sana Biotechnology's score of 0.47 indicating that Greenwich LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Greenwich LifeSciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Greenwich LifeSciences (GLSI) Competitors

$18.57 -1.23 (-6.21%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$18.50 -0.07 (-0.40%)

As of 07/13/2026 06:58 PM Eastern

Compare

GLSI vs. CALT, ORIC, CGEM, XNCR, and SANA

Should you buy Greenwich LifeSciences stock or one of its competitors? MarketBeat compares Greenwich LifeSciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Greenwich LifeSciences include Calliditas Therapeutics AB (publ) (CALT), Oric Pharmaceuticals (ORIC), Cullinan Therapeutics (CGEM), Xencor (XNCR), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry.

How does Greenwich LifeSciences compare to Calliditas Therapeutics AB (publ)?

Greenwich LifeSciences (NASDAQ:GLSI) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, Greenwich LifeSciences had 6 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 6 mentions for Greenwich LifeSciences and 0 mentions for Calliditas Therapeutics AB (publ). Greenwich LifeSciences' average media sentiment score of 1.02 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Greenwich LifeSciences is being referred to more favorably in the media.

Company	Overall Sentiment
Greenwich LifeSciences	Positive
Calliditas Therapeutics AB (publ)	Neutral

Greenwich LifeSciences has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Calliditas Therapeutics AB (publ)'s return on equity of -212.04% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-941.15%	-368.53%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Greenwich LifeSciences has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Greenwich LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Greenwich LifeSciences has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Greenwich LifeSciences currently has a consensus price target of $47.50, indicating a potential upside of 155.79%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Greenwich LifeSciences is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Greenwich LifeSciences beats Calliditas Therapeutics AB (publ) on 11 of the 15 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Oric Pharmaceuticals?

Greenwich LifeSciences (NASDAQ:GLSI) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Greenwich LifeSciences presently has a consensus target price of $47.50, indicating a potential upside of 155.79%. Oric Pharmaceuticals has a consensus target price of $19.27, indicating a potential upside of 84.25%. Given Greenwich LifeSciences' higher probable upside, equities research analysts clearly believe Greenwich LifeSciences is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A

In the previous week, Greenwich LifeSciences had 3 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 6 mentions for Greenwich LifeSciences and 3 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 1.77 beat Greenwich LifeSciences' score of 1.02 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenwich LifeSciences	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oric Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Oric Pharmaceuticals' return on equity of -35.33% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-941.15%	-368.53%
Oric Pharmaceuticals	N/A	-35.33%	-33.31%

Greenwich LifeSciences has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market.

4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Oric Pharmaceuticals beats Greenwich LifeSciences on 8 of the 13 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

In the previous week, Greenwich LifeSciences had 2 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 6 mentions for Greenwich LifeSciences and 4 mentions for Cullinan Therapeutics. Greenwich LifeSciences' average media sentiment score of 1.02 beat Cullinan Therapeutics' score of 0.87 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Greenwich LifeSciences	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cullinan Therapeutics' return on equity of -51.45% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Greenwich LifeSciences	N/A	-941.15%	-368.53%

Cullinan Therapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

Cullinan Therapeutics presently has a consensus price target of $32.00, indicating a potential upside of 79.07%. Greenwich LifeSciences has a consensus price target of $47.50, indicating a potential upside of 155.79%. Given Greenwich LifeSciences' higher probable upside, analysts plainly believe Greenwich LifeSciences is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A

Summary

Greenwich LifeSciences beats Cullinan Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Xencor?

Xencor (NASDAQ:XNCR) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Xencor currently has a consensus target price of $24.25, indicating a potential upside of 62.10%. Greenwich LifeSciences has a consensus target price of $47.50, indicating a potential upside of 155.79%. Given Greenwich LifeSciences' higher possible upside, analysts clearly believe Greenwich LifeSciences is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

4.2% of Greenwich LifeSciences shares are held by institutional investors. 5.1% of Xencor shares are held by insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Xencor had 1 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 7 mentions for Xencor and 6 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 1.02 beat Xencor's score of 0.65 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Greenwich LifeSciences	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Greenwich LifeSciences has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Greenwich LifeSciences	N/A	-941.15%	-368.53%

Xencor has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

Greenwich LifeSciences has lower revenue, but higher earnings than Xencor. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	8.83	-$91.92M	-$2.29	N/A
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A

Summary

Greenwich LifeSciences beats Xencor on 8 of the 15 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

In the previous week, Greenwich LifeSciences had 2 more articles in the media than Sana Biotechnology. MarketBeat recorded 6 mentions for Greenwich LifeSciences and 4 mentions for Sana Biotechnology. Greenwich LifeSciences' average media sentiment score of 1.02 beat Sana Biotechnology's score of 0.47 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Greenwich LifeSciences	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by company insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Sana Biotechnology's return on equity of -108.01% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Greenwich LifeSciences	N/A	-941.15%	-368.53%

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A

Sana Biotechnology presently has a consensus price target of $9.50, indicating a potential upside of 160.99%. Greenwich LifeSciences has a consensus price target of $47.50, indicating a potential upside of 155.79%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, equities research analysts plainly believe Sana Biotechnology is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Sana Biotechnology has a beta of 2.13, suggesting that its stock price is 113% more volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

Summary

Sana Biotechnology beats Greenwich LifeSciences on 9 of the 13 factors compared between the two stocks.

Get Greenwich LifeSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLSI vs. The Competition

Export

Metric	Greenwich LifeSciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$290.63M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-11.83	20.85	27.11	24.26
Price / Sales	N/A	314.01	587.92	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	619.00	8.49	10.75	6.29
Net Income	-$19.36M	$23.83M	$3.58B	$330.66M
7 Day Performance	N/A	-3.56%	-2.06%	-1.32%
1 Month Performance	-22.82%	6.31%	3.32%	-0.64%
1 Year Performance	71.79%	48.30%	26.35%	19.08%

Greenwich LifeSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLSI Greenwich LifeSciences	2.1571 of 5 stars	$18.57 -6.2%	$47.50 +155.8%	+71.3%	$290.63M	N/A	N/A	3	Positive News
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
ORIC Oric Pharmaceuticals	2.2781 of 5 stars	$10.98 +0.6%	$18.92 +72.3%	-5.8%	$1.14B	N/A	N/A	80	News Coverage
CGEM Cullinan Therapeutics	2.5962 of 5 stars	$18.46 +3.6%	$32.00 +73.4%	+132.1%	$1.14B	N/A	N/A	30	Gap Down
XNCR Xencor	2.2313 of 5 stars	$15.32 +2.9%	$24.25 +58.3%	+69.4%	$1.13B	$125.58M	N/A	280	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GLSI) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Greenwich LifeSciences (GLSI) Competitors

GLSI vs. CALT, ORIC, CGEM, XNCR, and SANA

How does Greenwich LifeSciences compare to Calliditas Therapeutics AB (publ)?

Summary

How does Greenwich LifeSciences compare to Oric Pharmaceuticals?

Summary

How does Greenwich LifeSciences compare to Cullinan Therapeutics?

Summary

How does Greenwich LifeSciences compare to Xencor?

Summary

How does Greenwich LifeSciences compare to Sana Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLSI vs. The Competition

Greenwich LifeSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Greenwich LifeSciences (GLSI) Competitors

GLSI vs. CALT, ORIC, CGEM, XNCR, and SANA

How does Greenwich LifeSciences compare to Calliditas Therapeutics AB (publ)?

Does the media refer more to GLSI or CALT?

Is GLSI or CALT more profitable?

Which has higher valuation and earnings, GLSI or CALT?

Which has more volatility & risk, GLSI or CALT?

Do analysts recommend GLSI or CALT?

Do institutionals & insiders believe in GLSI or CALT?

Summary

How does Greenwich LifeSciences compare to Oric Pharmaceuticals?

Do analysts recommend GLSI or ORIC?

Which has preferable earnings & valuation, GLSI or ORIC?

Does the media refer more to GLSI or ORIC?

Is GLSI or ORIC more profitable?

Which has more risk and volatility, GLSI or ORIC?

Do institutionals and insiders believe in GLSI or ORIC?

Summary

How does Greenwich LifeSciences compare to Cullinan Therapeutics?

Does the media prefer CGEM or GLSI?

Is CGEM or GLSI more profitable?

Which has more volatility & risk, CGEM or GLSI?

Do analysts rate CGEM or GLSI?

Do insiders and institutionals believe in CGEM or GLSI?

Which has better earnings & valuation, CGEM or GLSI?

Summary

How does Greenwich LifeSciences compare to Xencor?

Do analysts prefer XNCR or GLSI?

Do institutionals & insiders have more ownership in XNCR or GLSI?

Does the media favor XNCR or GLSI?

Is XNCR or GLSI more profitable?

Which has more volatility & risk, XNCR or GLSI?

Which has preferable valuation and earnings, XNCR or GLSI?

Summary

How does Greenwich LifeSciences compare to Sana Biotechnology?

Does the media favor SANA or GLSI?

Do institutionals and insiders have more ownership in SANA or GLSI?

Is SANA or GLSI more profitable?

Which has stronger valuation & earnings, SANA or GLSI?

Do analysts prefer SANA or GLSI?

Which has more risk and volatility, SANA or GLSI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLSI vs. The Competition

Greenwich LifeSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools